Submitted by web@researchtop... on Tue, 08/04/2020 - 18:47
- Listen to streaming audioright from your computer
- Download programto your desktop
- Subscribe to podcastto have this and future issues delivered to your iTunes library
| Track 1: | Introduction |
| Track 2: | Overview of PARP Inhibitors: Biologic Rationale and Mechanism of Action |
| Track 3: | Side Effects and Toxicities of PARP Inhibitors |
| Track 4: | PARP Inhibitors for Ovarian Cancer |
| Track 5: | PARP Inhibitors for Breast Cancer |
| Track 6: | PARP Inhibitors for Pancreatic Cancer |
| Track 7: | PARP Inhibitors for Prostate Cancer |
| FACULTY |
|
Maha Hussain, MD, FACP, FASCO Genevieve Teuton Professor of Medicine Division of Hematology/Oncology Deputy Director Robert H Lurie Comprehensive Cancer Center Northwestern University Feinberg School of Medicine Chicago, Illinois |
|
Ursula Matulonis, MD Chief, Division of Gynecologic Oncology Brock-Wilson Family Chair Dana-Farber Cancer Institute Professor of Medicine Harvard Medical School Boston, Massachusetts |
|
Philip A Philip, MD, PhD, FRCP Kathryn Cramer Endowed Chair in Cancer Research Professor of Oncology and Pharmacology Leader, GI and Neuroendocrine Oncology Karmanos Cancer Institute Wayne State University Detroit, Michigan |
|
Hope S Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education University of California, San Francisco Helen Diller Family Comprehensive Cancer Center San Francisco, California |
| MODERATOR |
| Neil Love, MD Research To Practice Miami, Florida |